

SAFETY DATA SHEETS

This SDS packet was issued with item:

078388914

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078074500 078082145 078082160 078082178 078082186 078388898 078388922 078388955 078388963 078388971
078398996 078399004 078445623 078480157 078669247 078694988 078697798 078697806 078697913 078879409
078879417 078879425 078879433 078879441 078879458 078879466 078879474 078879482 078907222 078907223
078907224 078907225 078907226 078907227 078907228 078907229 078907230

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078074534 078081962 078082152 078082194 078082202 078082210 078109097 078189578 078697814 078697822
078697830 078697871 078697889 078697897 078697905 078697921 078697939 078697947 078907555 078907556

MATERIAL SAFETY DATA SHEET

--
Vet-A-Mix,
A Division of LLOYD, Inc
Phone No. (712) 246-4000
Page 1 of 2

P.O. Box 130, Shenandoah, IA 51601-0130

Thyro-Tabs[®], levothyroxine sodium tablets USP

MSDS Date: 2/16/93 (Original)

12/19/95, 01/03/05, 5/26/06, 6/28/06 (Revised)

Product Name: Thyro-Tabs[®], levothyroxine sodium tablets USP

1. INGREDIENTS: (% w/w), unless otherwise noted

| COMPONENT | CAS# | % | EXPOSURE LIMITS, ppm | |
|----------------------|-----------|-------------|-----------------------------------|-----------------------------------|
| | | | OSHA PEL | ACGIH TLV (mg/m ³) |
| Polyvinylpyrrolidone | 9003-39-8 | 1.8 | TWA: 15 (total) 5 (respirable) | TWA: 10 (total) 5 (respirable) |
| Levothyroxine Sodium | 55-03-8 | 0.086-0.86* | --None Established-- | |

This document is prepared pursuant to the OSHA Hazard Communication Standard (29 CFR 1910.1200). Only those ingredients composing $\geq 1\%$ ($\geq 0.1\%$ for carcinogens or suspect carcinogens) of the formula (w/w) and which have hazards identified are listed. The exposure limits listed for polyvinylpyrrolidone are for nuisance dusts and not applicable in the solid dosage form.

* This product is available in potencies of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 and 1.0 mg levothyroxine sodium per tablet.

2. PHYSICAL DATA:

APPEARANCE: Color-coded and potency-embossed scored caplet-shaped tablet; 0.1 mg - yellow; 0.2 mg - pink; 0.3 mg - green; 0.4 mg - maroon; 0.5 mg - white; 0.6 mg - purple; 0.7 mg - orange; 0.8 mg - blue; and 1.0 mg - tan.

Other physical data have not been determined.

3. FIRE AND EXPLOSION HAZARD DATA:

This has not been evaluated.

EXTINGUISHING MEDIA: Water fog, alcohol foam, CO₂, dry chemical.

4. REACTIVITY DATA:

This has not been evaluated. The product is expected to be stable under normal storage conditions; avoid strong oxidizers. Levothyroxine sodium produces highly toxic iodine vapors as hazardous decomposition products.

5. ENVIRONMENTAL AND DISPOSAL INFORMATION:

ACTION TO TAKE FOR SPILLS/LEAKS: Sweep up and dispose of in DOT-approved waste containers. Keep out of sewers, storm drains, surface waters and soil.

DISPOSAL METHOD: Dispose of contaminated product and materials used in cleaning up spills or leaks in a manner approved for this material. Consult appropriate federal, state and local regulatory agencies to ascertain proper disposal procedures.

6. HEALTH HAZARD DATA:

Polyvinylpyrrolidone: May possibly cause skin irritation or dermatitis in some individuals upon prolonged contact. Oral LD50 (rat) : >100 g/kg

EYE: This product is not expected to irritate the eyes.

SKIN CONTACT: This product is not expected to irritate the skin.

INGESTION: This has not been evaluated.

MATERIAL SAFETY DATA SHEET

--

Vet-A-Mix,
A Division of LLOYD, Inc
Phone No. (712) 246-4000
Page 2 of 2

P.O. Box 130, Shenandoah, IA 51601-0130
Thyro-Tabs[®], levothyroxine sodium tablets USP
MSDS Date: 2/16/93 (Original)
12/19/95, 01/03/05, 5/26/06, 6/28/06 (Revised)

INHALATION: Inhalation exposure under normal conditions of use is not likely to cause adverse effects. Generation of dust or prolonged excessive exposure to dust should be avoided to prevent adverse health effects.

SIGNS AND SYMPTOMS OF EXPOSURE:

Levothyroxine Sodium: Effects of overexposure after ingestion includes nervousness, sweating, hyperhidrosis, insomnia, tachycardia, blood pressure variation and loss of weight.

7. FIRST AID:

EYES: Immediately flush eyes with copious amounts of running water for 15 minutes.

SKIN: Wash with soap and water.

INGESTION: SEEK MEDICAL ATTENTION IMMEDIATELY. Induce vomiting and follow up with symptomatic and supportive treatment.

INHALATION: If a person has been exposed to excessive quantities of dust due to mishaps, move the person to fresh air. Give artificial respiration if not breathing.

Seek medical attention immediately if excessive exposure occurs.

8. HANDLING PRECAUTIONS:

There is no OSHA PEL or ACGIH TLV for this product. Under normal conditions of use, no special handling precautions are required in areas with adequate ventilation. However, under conditions of prolonged exposure in which quantities of dust are generated, mechanical ventilation, safety glasses with side shields, gloves and a NIOSH approved dust respirator are recommended.

SPECIAL PRECAUTIONS TO BE TAKEN IN HANDLING AND STORAGE: Exercise reasonable care and caution.

REGULATORY INFORMATION: (Not meant to be all-inclusive--selected regulations represented.)

NOTICE: The information herein is presented in good faith and believed to be accurate as of the effective date shown above. However, no warranty, express or implied, is given. Regulatory requirements are subject to change and may differ from one location to another; it is the buyer's responsibility to ensure that its activities comply with federal, state or provincial, and local laws. The following specific information is made for the purpose of complying with numerous federal, state or provincial, and local laws and regulations. See MSDS for health and safety information.

U.S. REGULATIONS: SARA HAZARD CATEGORY: This product has been reviewed according to the federal EPA "Hazard Categories" promulgated under Sections 311 and 312 of the Superfund Amendment and Reauthorization Act of 1986 (SARA Title III) and is considered, under applicable definitions, to be exempt from reporting requirements. Nevertheless, potential reporters should check with their state emergency response commissions to determine if this product must be reported under applicable state requirements.